Background: Vulvodynia is a chronic vulvar pain syndrome with multifactorial etiology and unclear pathophysiology. Despite its high prevalence, it remains underdiagnosed and under-researched, with significant repercussions for women’s physical, psychological, and social well-being. Objective: To synthesize the available scientific evidence on quality of life (QoL) in women diagnosed with vulvodynia, identifying the main affected domains and the assessment tools used in the literature. Methods: A rapid review was conducted following PRISMA 2020 and Cochrane Rapid Reviews guidelines. Searches were performed in PubMed, Web of Science, Scopus, CINAHL, Biblioteca Virtual en Salud, and CUIDEN without date or geographic restrictions. Studies including adult women diagnosed with vulvodynia and reporting QoL outcomes were eligible. Data was extracted and synthesized narratively, and methodological quality was assessed using the Mixed Methods Appraisal Tool (MMAT). Results: Twenty studies published between 2006 and 2025 met the inclusion criteria (13 quantitative and 7 qualitative). Vulvodynia was consistently associated with reduced QoL across physical, psychological, and social dimensions. The most frequently reported issues were chronic vulvar pain, sexual dysfunction, anxiety, depression, and social withdrawal. Tools such as SF-12, SF-36, WHOQOL-BREF, DLQI, Skindex-29, and SQLQ-F were commonly used, although heterogeneity among instruments limited comparability. Multidisciplinary interventions combining physiotherapy and psychological therapy showed improvements in emotional and physical well-being, though sexual dysfunction often persisted. Conclusions: Vulvodynia substantially impairs women’s quality of life, reflecting complex biopsychosocial interactions. The findings highlight the need for standardized QoL measures and gender-sensitive, multidisciplinary approaches to diagnosis, management, and research.

Background: Vitamin K antagonist oral anticoagulant (VKA) therapy, using warfarin or acenocoumarol in our health system, is indicated, according to clinical guidelines, for the prophylaxis of thromboembolic events. In Málaga, the VKA patient management program currently includes a total of 856 patients. Hypothesis: The use of an AI-based application can enhance treatment adherence among VKA patients participating in self-monitoring and self-management programs. Furthermore, it can support the comprehensive implementation of the system, leading to reduced costs and fewer interventions for anticoagulated patients. Methods: The study will be conducted in several phases. The first phase involves the development of the application and the integration of Artificial Intelligence (AI) and Machine Learning (ML) algorithms. The second phase includes preliminary testing and validation of the developed application. The third phase consists of full implementation, along with an assessment of user-identified needs and potential quality improvements. Expected Results: The implementation of the AIto-Control app is expected to reduce healthcare-related costs by decreasing primary care visits and hospital admissions due to thromboembolic or bleeding events. Additionally, it aims to ease the workload on both primary care and hospital services. These outcomes will be achieved through the involvement of advanced practice nurses who will supervise app-based monitoring and patient education.